Literature DB >> 2990385

Analysis of the HSV-2 early AG-4 antigen.

L A Evans, M Sheppard, J T May.   

Abstract

Genital herpes simplex virus type 2 (HSV-2) infections can be distinguished from present or past HSV-1 infections by an AG-4 antigen complement fixation assay. The assay which utilizes a 4 hour HSV-2 infected cell extract prepared at a multiplicity of infection (MOI) of 1.0 PFU/cell, appears to consist of several viral proteins. Studies using monoclonal antibodies, polyclonal rabbit hyperimmune serum, HSV-1 X HSV-2 intertypic recombinant viruses and polyacrylamide gel electrophoresis suggest that ICP 8 may be one of the major antigens involved in the complement fixing reaction. It is probable that the success of the assay is not due to a true type specificity but rather a threshold phenomenon in which HSV-2 extracts contain more early viral antigens (including ICP 8) and sera from HSV-2 patients contain more complement fixing antibody to these antigens.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2990385     DOI: 10.1007/bf01317002

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  27 in total

1.  Anatomy of herpes simplex virus (HSV) DNA. X. Mapping of viral genes by analysis of polypeptides and functions specified by HSV-1 X HSV-2 recombinants.

Authors:  L S Morse; L Pereira; B Roizman; P A Schaffer
Journal:  J Virol       Date:  1978-05       Impact factor: 5.103

2.  Comparative analyses of the proteins and antigens of five herpesviruses.

Authors:  R A Killington; J Yeo; R Honess; D H Watson; B E Duncan; I W Halliburton; J Mumford
Journal:  J Gen Virol       Date:  1977-11       Impact factor: 3.891

3.  Antigens of Herpes simplex virus type 1 and 2-immunodiffusion and inhibition passive hemagglutination studies.

Authors:  K E Schneweis; A J Nahmias
Journal:  Z Immunitatsforsch Exp Klin Immunol       Date:  1971-06

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Typing of herpes simplex virus strains by analysis of the early proteins.

Authors:  M H Wolff; A Zoll; K E Schneweis
Journal:  Med Microbiol Immunol       Date:  1982       Impact factor: 3.402

6.  AG-4 complement-fixing antibodies in cervical cancer and herpes-infected patients using local herpes simplex virus type 2.

Authors:  M Arsenakis; G M Georgiou; J K Welsh; M N Cauchi; J T May
Journal:  Int J Cancer       Date:  1980-01-15       Impact factor: 7.396

7.  Identification and preliminary mapping with monoclonal antibodies of a herpes simplex virus 2 glycoprotein lacking a known type 1 counterpart.

Authors:  B Roizman; B Norrild; C Chan; L Pereira
Journal:  Virology       Date:  1984-02       Impact factor: 3.616

8.  THE FORMATION AND PROPERTIES OF POLIOVIRUS-NEUTRALIZING ANTIBODY. II. 19S AND 7S ANTIBODY FORMATION: DIFFERENCES IN ANTIGEN DOSE REQUIREMENT FOR SUSTAINED SYNTHESIS, ANAMNESIS, AND SENSITIVITY TO X-IRRADIATION.

Authors:  S E SVEHAG; B MANDEL
Journal:  J Exp Med       Date:  1964-01-01       Impact factor: 14.307

9.  Determination of herpes simplex virus type-specific antibodies by solid-phase RIA on Helix pomatia lectin-purified antigens.

Authors:  A Suchánková; I Hirsch; M Krĕmár; V Vonka
Journal:  J Infect Dis       Date:  1984-06       Impact factor: 5.226

10.  Confirmation of herpes simplex virus type 2 infections in herpes-like genital lesions by a simple complement-fixation test.

Authors:  M Arsenakis; J T May
Journal:  Br J Vener Dis       Date:  1982-02
View more
  2 in total

1.  Type specificity of complement-fixing antibody against herpes simplex virus type 2 AG-4 early antigen in patients with asymptomatic infection.

Authors:  C H Sherlock; R L Ashley; M L Shurtleff; K D Mack; L Corey
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

2.  Herpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine.

Authors:  Joshua J Geltz; Edward Gershburg; William P Halford
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.